Facebook
X
LinkedIn
ForwardBiosimilars update – Things pharmacists need to know Homestudy
Target Audience
All pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to:
- Compare and contrast the biologics, biosimilars, and interchangeable biosimilars
- Describe the current role of pharmacists in selecting biologic therapies
- Summarize the current FDA guidelines for interchangeable biosimilars
- Discuss the current changes being considered with interchangeability guidelines
Philip J. Schneider, MS, FASHP, FASPEN, FFIP, Adjunct Professor - Practice, Division of Practice and Science, College of Pharmacy, The Ohio State University
Philip J. Schneider is Adjunct Professor - Practice, Division of Practice and Science, College of Pharmacy, The Ohio State University where he teaches in the Master of Science in Health-System Pharmacy Administration and Leadership coursework and assists with the College’s professional development activities.
He is principal of MediHealthInsight, LLC that provides consultation to the industry and others on matters related to improving the use of medicines including the application of new technologies in healthcare.
He is Chair for the International Advisory Board of the Alliance for Safe Biologic Medicines that serve as an authoritative resource center of information for the public, as well as the healthcare and health policy communities, on the issues surrounding biologic medications.
ACPE UAN 0042-0000-25-053-H99-P
Available Credit
- 1.00 ACPEThe Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.